Registration - In-house Corporation

Sandoz Canada Inc. / Michel Robidoux, President & Chief Executive Officer

Registration Information

In-house Corporation name: Sandoz Canada Inc.
Responsible Officer Name: Michel Robidoux, President & Chief Executive Officer
Responsible Officer Change History
Initial registration start date: 2009-01-01
Registration status: Active
Registration Number: 768899-234283

Associated Communications

Total Number of Communication Reports: 79

Monthly communication reports in the last 6 months: 5

Version 14 of 34 (2018-01-23 to 2018-04-09)

Registration versions:

Version 14 of 34 (2018-01-23 to 2018-04-09)

Lobbying Information

Subject Matters

Consumer Issues
Health
Industry
Intellectual Property
International Trade
Justice and Law Enforcement
Science and Technology

Subject Matter Details

Legislative Proposal, Bill or Resolution

Innovation, Science & Economic Development Canada regarding export provisions of the Patent Act (pharmaceuticals).
Innovation, Science & Economic Development, with respect to the Patent Act as it pertains to pharmaceuticals.
Provide input into the Government of Canada's negotiations regarding the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) and re-negotiation of NAFTA with respect to pharmaceuticals, counterfeit medicines, border measures and intellectual property.

Legislative Proposal, Bill or Resolution, Regulation

Health Canada regarding the Cannabis Act (C-45) and its Regulations for medicinal cannabis

Policies or Program

Health Canada regarding the development and implementation of an approval pathway for Biosimilars as well as pricing policies.
Health Canada regarding the need for appropriate, dedicated resources for the Therapeutic Products Directorate to meet performance targets for the review of generic drug submissions.
Health Canada, Innovation, Science & Economic Development Canada and International Trade Canada regarding effective measures to combat counterfeit drugs in Canada and around the world.
Provide input into Government of Canada's Science and Technology strategy regarding the need for a balanced Intellectual Property regime and the important role competition plays in encouraging innovation.

Regulation

As a member company, participation in the Canadian Generic Pharmaceutical Association's legal challenge of the 2006 Amendments to Health Canada's Food and Drug Regulations with respect to the extended period of data exclusivity, as well as further proposed amendments to these regulations.
Health Canada regarding regulation about Requirement for reporting of drug shortages.
Health Canada regarding the modernization of the Food and Drug Act (formerly Bill C-51) with respect to the development and implementation of a Progressive Licensing Framework for pharmaceuticals.
Innovation, Science & Economic Development Canada regarding the need to restore balance to the Patented Medicines (Notice of Compliance) Regulations with respect to pharmaceuticals and address operational concerns including: lack of finality to proceedings under the Regulations and lack of disincentives to discourage abuse of the Regulations.

Communication Techniques

Written communication
Oral communication

Government Institutions

Canada Border Services Agency (CBSA)
Canada Revenue Agency (CRA)
Competition Tribunal (CT)
Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Innovation, Science and Economic Development Canada (ISED)
Justice Canada (JC)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Public Health Agency of Canada (PHAC)
Senate of Canada
Treasury Board Of Canada Secretariat (TBS)

In-house Corporation Details

Description of activities

Sandoz, a division of the Novartis group, is a global leader in the field of generic pharmaceuticals and has a portfolio of more than 840 molecules in over 5,000 Stock Keeping Units in various concentrations, formats and delivery systems. Sandoz products are sold in more than 110 countries worldwide. Sandoz Canada Inc. is one of the very few sites amongst the Sandoz group that combines product development, manufacturing, commercialization and distribution, specializing in the development and manufacture of sterile injectables and ophthalmics. The company currently employs over 700 employees.

Responsible officer name and position during the period of this registration

Michel Robidoux, President & Chief Executive Officer

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
145 Jules-Léger Street
Boucherville, QC J4B 7K8
Canada

Telephone number: 450-641-4903 Ext. 2598
Fax number: 450-641-8615

Parent Company Information

Novartis Pharma Canada Inc.
- 385 Bouchard Boulevard
  Dorval, QC H9S 1A9
  Canada

Subsidiary Beneficiary Information

Sandoz Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Len Arsenault, Vice-President, Scientific Affairs | Public offices held
Vincenzo Ciampi, Executive Director, Innovation and Strategic Projects | No public offices held
Christian Danis, Vice-President, Legal and Government Affairs | No public offices held
Leonor Ferreira, Strategic Pricing Manager | No public offices held
Marc-André Huot, Directeur des brevets | No public offices held
Carmen Pedro, Director, Market Access Biosimilars | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Christian Ouellet, Directeur des affaires gouvernementales | No public offices held

Sandoz Canada Inc.

The following names have been used on or after July 2, 2008

The following names have been used on or after July 2, 2008
Name	From	To
Sandoz Canada Inc.	2009-01-01	current

Sandoz Canada Inc.

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Michel Robidoux	2010-04-01	Current
Pierre Fréchette	2009-01-01	2010-04-01

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Manager, Oral Products Unit Health Canada, Pharmaceutical Quality	1996 to March 1999	Not a designated office
A/Head, CMC Section Health Canada, Biopharmaceutical Evaluation	1994 to 1994	Not a designated office
A/Manager Health Canada, DIN products Unit	1994 to 1994	Not a designated office
Senior Evaluator Health Canada, Sterile Products and Oral Product Divisions	1991 to 1996	Not a designated office
Pharmaceutical evaluation officer Health Canada, Pharmaceutical Quality	1987 to 1991	Not a designated office

Date Modified:: 2025-03-12

Search and menus

Language selection

Registration - In-house Corporation

Sandoz Canada Inc. / Michel Robidoux, President & Chief Executive Officer

Registration Information

Associated Communications

Version 14 of 34 (2018-01-23 to 2018-04-09)

Version 14 of 34 (2018-01-23 to 2018-04-09)

Subject Matters

Subject Matter Details

Legislative Proposal, Bill or Resolution

Legislative Proposal, Bill or Resolution, Regulation

Policies or Program

Regulation

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties